The health worker and HIV in high-incidence poor countries: Part 1 — HIV and the health worker

Tropical Doctor

Volumn 30, Issue 3, 2000, Pages 175-177

  Cairns, James ^a  

^a St Francis Hospital Katete   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ARTICLE; COST; DISEASE TRANSMISSION; HEALTH CARE PERSONNEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; PROTECTION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; NEEDLESTICK INJURIES; RISK FACTORS; UNIVERSAL PRECAUTIONS;

EID: 0033938687     PISSN: 00494755     EISSN: 17581133     Source Type: Journal    
DOI: 10.1177/004947550003000323     Document Type: Article

References (8)

1. N'Galy B, Mann JM et al. HIV infection among employees in an African Hospital. N Engl J Med, 1988;319:1123-7.
2. Tokars I, Marcus R, Culver DH et al. CDC Cooperative Needlestick Surveillance Group. Surveillance of HIV infection and zidovudine used amongst health care workers after occupational exposure to HIV-infected blood. Ann Intern Med, 1993;118:913-18.
3. Henderson DK. HIV-1 in the health care setting. In: Mandel GL, Bennett JE, Dolan R, eds. Principles and Practice of Infectious Diseases, 4th edn. New York: Churchill Livingstone, 1996:2632-56.
4. Centers for Disease Control and Prevention (CDC). Case controlled study of HIV sero-conversion in health care workers after percutaneous exposure to HIV-infected blood — France, United Kingdom and United States January 1988 to August 1994. Morb Mortal Wekly Rep, 1995;44:929-33.
5. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. Morb Mortal Wkly Rep, 1996;45:468-80.
6. Centers for Disease Control and Prevention. Public Health Services guidelines for health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Morb Mortal Wkly Rep, 1998;47:1-33.
7. Collier J. Editorial. Drug Therapeut Bull, 1997;35:25-9.
8. Glaxo-Wellcome. Information. London: Glaxo Wellcome, August 1999.